Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review

OBJECTIVE: The recent American Society of Clinical Oncology (ASCO) Clinical Guidelines for chemotherapy-induced peripheral neuropathy (CIPN) management (48 Phase III trials reviewed) only recommend duloxetine. However, before concluding that a CIPN intervention is ineffective, scientists and clinici...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Deborah, Kanzawa-Lee, Grace, Knoerl, Robert, Wyatt, Gwen, Smith, Ellen M. Lavoie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696803/
https://www.ncbi.nlm.nih.gov/pubmed/31572750
http://dx.doi.org/10.4103/apjon.apjon_14_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696803/
https://www.ncbi.nlm.nih.gov/pubmed/31572750
http://dx.doi.org/10.4103/apjon.apjon_14_19

Ejemplares similares